Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at weekly chemotherapy for ovarian cancer (ICON 8)
This trial compared chemotherapy every week with chemotherapy every 3 weeks for ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It was supported by Cancer Research UK.
More about this trial
- is better than 3 weekly chemotherapy for women with ovarian cancer
- causes more or fewer side effects than 3 weekly chemotherapy
Summary of results
- 522 women had both carboplatin and paclitaxel once every 3 weeks (group A)
- 523 women had carboplatin once every 3 weeks, and paclitaxel once a week (group B)
- 521 women had both carboplatin and paclitaxel once a week (group C)
- 24.4 months for those in group A (3 weekly chemotherapy)
- 24.9 months for those in group B (3 weekly carboplatin and weekly paclitaxel)
- 25.3 months for those in group C (weekly chemotherapy)
- 8 out of 10 (80%) of those in group A
- just over 8 out of 10 (82%) of those in group B
- just under 8 out of 10 (78%) of those in group C
How to join a clinical trial
Dr Andrew Clamp
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/10/030.